Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onartuzumab + Erlotinib in Advanced NSCLC
NCT00854308Phase 2Completed
- Sponsor
- Genentech
- Start
- Apr 2009
- Primary completion
- Nov 2010
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of onartuzumab in non-small cell lung cancer (NSCLC), sponsored by Genentech. Started Apr 2009; status: completed.
02
Drugs
onartuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00854308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00854308.